News
BNTX
87.89
+1.63%
1.41
Pfizer's Doldrums, Just A Bad Case Of COVID-19?
Pfizer's dividend has reached the sky-high 6% mark. The company is following a similar trajectory to GILD in its post-HCV stagnation. PFE may be worth buying as the company's COVID-based product revenues decline and equilibrate. Company is working to develop a vaccine for the pandemic.
Seeking Alpha · 5h ago
ANALYSIS-Fragmented Europe to make new bid for US-style capital market
Fragmented Europe to make bid for US-style capital market. EU has 27 capital markets with a maze of different securities laws, taxes and accounting. About 250 billion euros a year leaves the EU to go elsewhere to grow in the U.S. EU leaders to focus on creating a true Capital Markets Union this week.
Reuters · 1d ago
Weekly Report: what happened at BNTX last week (0408-0412)?
Weekly Report · 1d ago
Pfizer wins pause on Moderna's COVID-19 patent lawsuit
Pfizer wins pause on Moderna's COVID-19 patent lawsuit claiming Pfizer copied its vaccine technology. Moderna accused Pfizer and BioNTech of violating its patent rights in messenger-RNA technology. The U.S. Patent Office will review two of the three Moderna patents at issue.
Reuters · 3d ago
Election Year Encore: Can 2020’s Top 7 Stock Winners Repeat Their Performance in 2024?
Investorplace · 6d ago
BioNTech SE Virtual AGM Scheduled for May 2024
TipRanks · 04/08 21:27
BioNTech Reports Promising Cancer Vaccine Data
TipRanks · 04/08 11:57
Weekly Report: what happened at BNTX last week (0401-0405)?
Weekly Report · 04/08 09:04
Reported Sunday, BioNTech Three-Year Phase 1 Follow-Up Data For mRNA-based Individualized Immunotherapy Candidate Shows Persistence Of Immune Response And Delayed Tumor Recurrence In Some Patients With Resected Pancreatic Cancer
Autogene cevumeran shows polyspecific T cell responses up to three years and delayed tumor recurrence in patients with resected pancreatic ductal adenocarcinoma. The medical need in PDAC is high with a 5-year overall survival rate of only 8-10%.
Benzinga · 04/08 06:45
BRIEF-Phase I Data Show Polyspecific T Cell Responses Up To Three Years And Delayed Tumor Recurrence In Patients With Resected Pancreatic Ductal Adenocarcinoma (“PDAC”)
BioNTech says phase I data show Polyspecific T Cell Responses Up To Three years And Delayed Tumor Recurrence In Patients With Resected Pancreatic Ductal Adenocarcinoma. The drug is being tested on patients with the disease.
Reuters · 04/08 05:42
CureVac, GS Partner Release Data On Influenza Vaccine Study
CureVac N.V. Released interim data on its seasonal influenza vaccine candidate. The study is part of a collaboration with GSK Plc. The multivalent candidate is designed for broad antigen coverage and is matched to all four WHO-recommended flu strains.
Benzinga · 04/04 16:18
Weekly Report: what happened at BNTX last week (0325-0329)?
Weekly Report · 04/01 09:05
BioNTech Is Maintained at Neutral by UBS
Dow Jones · 03/27 18:24
BioNTech Price Target Cut to $101.00/Share From $110.00 by UBS
Dow Jones · 03/27 18:24
UBS Maintains Neutral on BioNTech, Lowers Price Target to $101
Benzinga · 03/27 18:14
Moderna (MRNA) Posts Upbeat Data From Next-Gen COVID Jab Study
NASDAQ · 03/27 16:24
We Think You Can Look Beyond BioNTech's (NASDAQ:BNTX) Lackluster Earnings
BioNTech SE's (NASDAQ:BNTX) reported a lackluster earnings report last week. The company's free cash flow dwarfed its reported profit of €930.3m. Its accrual ratio is a good measure of how well a company converts its profits into free cashflow. BioNTech has a negative ratio of -0.77, and its statutory earnings are less than its free cash flows. However, the company's EPS is growing strongly and could be under-estimating its earnings potential.
Simply Wall St · 03/27 10:18
UPDATE 1-BioNTech gets notice from US agency over default on COVID vaccine royalties
BioNTech says U.S. National Institutes of Health has sent a to the German company over default in the payment of royalties. The dispute relates to its COVID-19 vaccine for which it partnered with Pfizer. The company says it intends to defend against all allegations of breach.
Reuters · 03/25 10:47
BioNTech gets notice from NIH on default on royalties
BioNTech gets from NIH on default on royalties and other amounts it allegedly owed the agency. The company says it has received a from the U.S. National Institutes of Health over default in payment of royalties. BioNTech 22UAy.DE said on Monday.
Reuters · 03/25 10:19
Weekly Report: what happened at BNTX last week (0318-0322)?
Weekly Report · 03/25 09:04
More
Webull provides a variety of real-time BNTX stock news. You can receive the latest news about BIONTECH through multiple platforms. This information may help you make smarter investment decisions.
About BNTX
BioNTech SE is a Germany-based clinical-stage biotechnology company. The Company focuses on patient-specific immunotherapies for the treatment of cancer and other serious diseases. The Company is providing technologies including mRNA-based therapies, cell therapies, small molecules and antibodies, which can be utilized for specific purposes or can be even combined with each other in a synergistic manner. It also develops a broad product pipeline using different scientific approaches and technology platforms, including individualized mRNA-based product candidates, chimeric antigen receptor T-cells, checkpoint immunomodulators, targeted cancer antibodies and small molecules. In addition, the Company offers diagnostic products and drug discovery services for other therapeutic areas, including infectious diseases, allergies and autoimmune disorders.